Is tucatinib/tucatinib available in the country?

Tucatinib is a highly selective HER2 tyrosine kinase inhibitor used to treat patients with HER2-positive breast cancer and brain metastases. It reduces the proliferation and spread of tumor cells by blocking theHER2 signaling pathway, and has become one of the indispensable targeted drugs in multi-line treatment. The drug was first developed by the American company Seagen, with the trade name TUKYSA. It has been approved for marketing in the United States, the European Union, Canada, Japan and other countries. However, as of 2025, the original drug tucatinib has not yet been officially launched in mainland China or approved by the State Food and Drug Administration, so it is temporarily not available for direct purchase in domestic hospitals and pharmacies.

Currently, if domestic patients need to use tucatinib, they usually obtain it through legal cross-border drug purchase channels or overseas medical service institutions. The specifications of the European version of the original drug are generally 150 mg × 84 tablets, and the price per box is more than 40,000 yuan. The price will change with exchange rates and market fluctuations. In comparison, some Southeast Asian countries (such as Laos) have launched generic versions of tucatinib, with a specification of 150 mg × 60 tablets and a price of only about 2,000 yuan. The ingredients and dosage are basically the same as the original drug, providing patients with a lower-cost option.

In overseas markets, tucatinib has attracted much attention because it can be used in combination with trastuzumab and capecitabine to significantly extend the survival of patients with HER2-positive breast cancer. Especially for patients with brain metastases, tucatinib exhibits strong penetration into the central nervous system, which is its unique advantage compared with other HER2-targeted drugs.

Taken together, although tucatinib has not yet been officially launched in China, its efficacy and safety have been widely recognized globally. In the future, with the advancement of domestic clinical research and approval processes, tucatinib is expected to be approved in the Chinese market, allowing more patients to conveniently and safely obtain this innovative treatment option.

Reference materials:https://www.tukysa.com/